» Articles » PMID: 32838264

Placental Transfer and Safety in Pregnancy of Medications Under Investigation to Treat Coronavirus Disease 2019

Overview
Date 2020 Aug 25
PMID 32838264
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Treatment of coronavirus disease 2019 is mostly symptomatic, but a wide range of medications are under investigation against severe acute respiratory syndrome coronavirus 2. Although pregnant women are excluded from clinical trials, they will inevitably receive therapies whenever they seem effective in nonpregnant patients and even under compassionate use.

Methods: We conducted a review of the literature on placental transfer and pregnancy safety data of drugs under current investigation for coronavirus disease 2019.

Results: Regarding remdesivir, there are no data in pregnant women. Several other candidates already have safety data in pregnant women, because they are repurposed drugs already used for their established indications. Thus, they may be used in pregnancy, although their safety in the context of coronavirus disease 2019 may differ from conventional use. These include HIV protease inhibitors such as lopinavir/ritonavir that have low placental transfer, interferon that does not cross the placental barrier, and hydroxychloroquine or chloroquine that has high placental transfer. There are also pregnancy safety and placental transfer data for colchicine, steroids, oseltamivir, azithromycin, and some monoclonal antibodies. However, some drugs are strictly prohibited in pregnancy because of known teratogenicity (thalidomide) or fetal toxicities (renin-angiotensin system blockers). Other candidates including tocilizumab, other interleukin 6 inhibitors, umifenovir, and favipiravir have insufficient data on pregnancy outcomes.

Conclusion: In life-threatening cases of coronavirus disease 2019, the potential risks of therapy to the fetus may be more than offset by the benefit of curing the mother. Although preclinical and placental transfer studies are required for a number of potential anti-severe acute respiratory syndrome coronavirus 2 drugs, several medications can already be used in pregnant women.

Citing Articles

Two successful pregnancies -in patients taking Volanesorsen for familial chylomicronemia syndrome.

Wanninayake S, Ochoa-Ferraro A, Patel K, Ramachandran R, Wierzbicki A, Dawson C JIMD Rep. 2024; 65(4):249-254.

PMID: 38974616 PMC: 11224504. DOI: 10.1002/jmd2.12435.


Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.

Zendedel E, Tayebi L, Nikbakht M, Hasanzadeh E, Asadpour S Curr Stem Cell Res Ther. 2023; 19(8):1055-1071.

PMID: 37815188 DOI: 10.2174/011574888X260032230925052240.


The clinical characteristics of COVID-19 omicron variant infection in pregnant women and their neonates.

Liu L, Lin L, Lin F, Yang Y, Lin C, Zhang L Front Med (Lausanne). 2023; 10:1229794.

PMID: 37780575 PMC: 10537922. DOI: 10.3389/fmed.2023.1229794.


Evolution of National Guidelines on Medicines Used to Treat COVID-19 in Pregnancy in 2020-2022: A Scoping Review.

Maisonneuve E, de Bruin O, Favre G, Gonce A, Donati S, Engjom H J Clin Med. 2023; 12(13).

PMID: 37445553 PMC: 10342271. DOI: 10.3390/jcm12134519.


Maternal antibiotic administration during gestation can affect the memory and brain structure in mouse offspring.

Shepilov D, Osadchenko I, Kovalenko T, Yamada C, Chereshynska A, Smozhanyk K Front Cell Neurosci. 2023; 17:1176676.

PMID: 37234915 PMC: 10206017. DOI: 10.3389/fncel.2023.1176676.


References
1.
Fauchet F, Treluyer J, Illamola S, Pressiat C, Lui G, Valade E . Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment. Antimicrob Agents Chemother. 2015; 59(9):5727-35. PMC: 4538471. DOI: 10.1128/AAC.00863-15. View

2.
Waysbort A, Giroux M, Mansat V, Teixeira M, Dumas J, Puel J . Experimental study of transplacental passage of alpha interferon by two assay techniques. Antimicrob Agents Chemother. 1993; 37(6):1232-7. PMC: 187945. DOI: 10.1128/AAC.37.6.1232. View

3.
Gavard L, Beghin D, Forestier F, Cayre Y, Peytavin G, Mandelbrot L . Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir. Eur J Obstet Gynecol Reprod Biol. 2009; 147(2):157-60. DOI: 10.1016/j.ejogrb.2009.08.007. View

4.
Delang L, Abdelnabi R, Neyts J . Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018; 153:85-94. DOI: 10.1016/j.antiviral.2018.03.003. View

5.
Simon A, Warszawski J, Kariyawasam D, Chenadec J, Benhammou V, Czernichow P . Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA. 2011; 306(1):70-8. DOI: 10.1001/jama.2011.915. View